Workshop
Event Title
FDA- United States Pharmacopeia (USP) Asia-Pacific Economic Cooperation (APEC) Medical Product Supply Chain Dialogue
April 25 - 26, 2023
- Date:
- April 25 - 26, 2023
- Day1:
- - ET
- Day2:
- - ET
- Location:
-
Event LocationAttend Online or
USP Rockville
12601 Twinbrook Parkway
Rockville, MD 20852
United States
Attend
FDA and United States Pharmacopeia (USP) are cosponsoring the Asia-Pacific Economic Cooperation (APEC) Medical Product Supply Chain Dialogue. This program aims to accelerate APEC and global efforts to strengthen the resilience of global medical product supply chains. This meeting will bring international medical product regulators, multilateral organization representatives, and industry and academic professionals together, to discuss public health priorities, the impact of the COVID-19 pandemic on supply chains, and why the APEC Supply Chain Security Toolkit continues to be a valuable tool to stakeholders.
This event is open to the public and free of cost.
Topics will include:
- APEC Roadmap to promote global medical product quality and supply chain security
- Identifying vulnerabilities in the upstream supply chain
- Mitigating and managing risks in raw material quality and supply chain security
- Manufacturing solutions to strengthen global supply chain resilience
- Experiences strengthening quality assurance in the Asia Pacific
- Safeguarding patients from impurities in the drug supply chain
- The supply chain imperative to fight AMR
- Securing the downstream supply chain - good distribution practices & post-marketing surveillance
- Securing the downstream supply chain - internet pharmacies
Contact
For questions, please email RFD@USP.org.
Additional Information
- Asia Pacific Economic Cooperation (APEC) Supply Chain Security Toolkit for Medical Products
- Asia-Pacific Economic Cooperation (apec.org)
- US Pharmacopeia (USP)
- USP-APEC Center of Excellence for Securing Medical Product Quality Through the Supply Chain
- FDA Office of Compliance, Office of Drug Security, Integrity, and Response
- FDA Office of Global Policy and Strategy